PACKAGING TECHNOLOGY CASE STUDIES

Verta Life Sciences have extensive experience helping clients select the most suitable packaging technology for a broad range of pharmaceutical products. Our expertise covers the selection and specification of packaging materials and process, including blow molded and injection molded components, glass, metal, films, paperboard and corrugated. Areas of prime interest include innovation, anticounterfeiting, operational improvements, packaging technology, packaging transfers, primary and secondary packaging processes, labeling & graphic design processes, pack design, packaging start-ups and product/package/process trouble shooting.

PACKAGING DAMAGED DURING TRANSIT CASE STUDY

ISSUE:
A client was experiencing complaints from customers about damaged finished pharmaceutical packs on receipt at the customer’s warehouse.

OBJECTIVE:
Review client’s current packaging specifications and transit procedures.

DELIVERABLE:
Short term: Provided a “quick fix” for the first 3 months of orders, which increased the current cost-of-goods but less than the current cost of product damages and loss of customer “good will”.

Long term: Complete redesign of the secondary and tertiary packaging components as well as the pallet configuration. Design criteria confirmed by lab testing and then implemented. Results were a reduction in the overall cost-of-goods and no damages to finished product.

PACKAGING RELATED STABILITY FAILURE CASE STUDY

ISSUE:
A client’s new solid dose product was failing accelerated stability testing due to moisture ingress.
**OBJECTIVE:**
Review current product manufacturing and packaging process and moisture requirements as well as the specifications of the container/closure system.

**DELIVERABLE:**
Identified changes to the capsule manufacturing process to reduce moisture.
Identified alternative container/closure systems that minimized the possibility of moisture ingress.
Identified changes required to packaging line and recommended changes to packaging process
Moisture ingress problem resolved and confirmed allowing client to include final pack stability in the FDA submission.